Literature DB >> 32553250

Complement and the Kidney: An Overview.

Joshua M Thurman1.   

Abstract

The complement cascade was first recognized as a downstream effector system of antibody-mediated cytotoxicity. Consistent with this view, it was discovered in the 1960s that complement is activated in the glomeruli of patients with immune complex glomerulonephritis. More recently, research has shown that complement system has many additional functions relating to regulation of the immune response, homeostasis, and metabolism. It has also become clear that the complement system is important to the pathogenesis of many non-immune complex mediated kidney diseases. In fact, in atypical hemolytic uremic syndrome and C3 glomerulopathy, uncontrolled complement activation is the primary driver of disease. Complement activation generates multiple pro-inflammatory fragments, and if not properly controlled it can cause fulminant tissue injury. Furthermore, the mechanisms of complement activation and complement-mediated injury vary from disease to disease. Many new drugs that target the complement cascade are in clinical development, so it is important to fully understand the biology of the complement system and its role in disease.
Copyright © 2019 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibody-mediated allograft rejection; Complement; Diagnostics; Glomerulonephritis; Inflammation; Therapeutics

Mesh:

Substances:

Year:  2020        PMID: 32553250      PMCID: PMC7310605          DOI: 10.1053/j.ackd.2019.10.003

Source DB:  PubMed          Journal:  Adv Chronic Kidney Dis        ISSN: 1548-5595            Impact factor:   3.620


  84 in total

1.  Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome.

Authors:  Fengxiao Bu; Tara Maga; Nicole C Meyer; Kai Wang; Christie P Thomas; Carla M Nester; Richard J H Smith
Journal:  J Am Soc Nephrol       Date:  2013-09-12       Impact factor: 10.121

2.  Complement deposition in glomerular diseases.

Authors:  G B di Belgiojoso; A Tarantino; A Durante; L Guerra
Journal:  Proc Eur Dial Transplant Assoc       Date:  1975

3.  C3a is required for the production of CXC chemokines by tubular epithelial cells after renal ishemia/reperfusion.

Authors:  Joshua M Thurman; Amanda M Lenderink; Pamela A Royer; Kathrin E Coleman; Jian Zhou; John D Lambris; Raphael A Nemenoff; Richard J Quigg; V Michael Holers
Journal:  J Immunol       Date:  2007-02-01       Impact factor: 5.422

4.  Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis.

Authors:  Peter N Lalli; Michael G Strainic; Min Yang; Feng Lin; M Edward Medof; Peter S Heeger
Journal:  Blood       Date:  2008-06-20       Impact factor: 22.113

5.  High-Throughput Genetic Testing for Thrombotic Microangiopathies and C3 Glomerulopathies.

Authors:  Fengxiao Bu; Nicolo Ghiringhelli Borsa; Michael B Jones; Erika Takanami; Carla Nishimura; Jill J Hauer; Hela Azaiez; Elizabeth A Black-Ziegelbein; Nicole C Meyer; Diana L Kolbe; Yingyue Li; Kathy Frees; Michael J Schnieders; Christie Thomas; Carla Nester; Richard J H Smith
Journal:  J Am Soc Nephrol       Date:  2015-08-17       Impact factor: 10.121

6.  Activation of the alternative pathway of complement by human serum IgA.

Authors:  P S Hiemstra; A Gorter; M E Stuurman; L A Van Es; M R Daha
Journal:  Eur J Immunol       Date:  1987-03       Impact factor: 5.532

Review 7.  Diagnostic significance of hypocomplementemia.

Authors:  L A Hebert; F G Cosio; J C Neff
Journal:  Kidney Int       Date:  1991-05       Impact factor: 10.612

Review 8.  Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H.

Authors:  S Rodríguez de Córdoba; E Goicoechea de Jorge
Journal:  Clin Exp Immunol       Date:  2008-01       Impact factor: 4.330

Review 9.  Complement Therapeutics in Autoimmune Disease.

Authors:  Joshua M Thurman; Roshini Yapa
Journal:  Front Immunol       Date:  2019-04-03       Impact factor: 7.561

10.  Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains.

Authors:  Matthew C Pickering; Elena Goicoechea de Jorge; Rubén Martinez-Barricarte; Sergio Recalde; Alfredo Garcia-Layana; Kirsten L Rose; Jill Moss; Mark J Walport; H Terence Cook; Santiago Rodriguez de Córdoba; Marina Botto
Journal:  J Exp Med       Date:  2007-05-21       Impact factor: 14.307

View more
  6 in total

1.  The Association Between Serum Complement 4 and Kidney Disease Progression in Idiopathic Membranous Nephropathy: A Multicenter Retrospective Cohort Study.

Authors:  Jing Liu; Yang Zha; Peng Zhang; Peng He; Lijie He
Journal:  Front Immunol       Date:  2022-05-30       Impact factor: 8.786

Review 2.  Regulation of Complement Activation by Heme Oxygenase-1 (HO-1) in Kidney Injury.

Authors:  Maria G Detsika; Elias A Lianos
Journal:  Antioxidants (Basel)       Date:  2021-01-06

3.  Serum Level of Complement C1q is Associated with Contrast-Associated Acute Kidney Injury in Patients Undergoing Emergency Percutaneous Coronary Intervention.

Authors:  Jun Tao; Chenglin Ye; Wen Dai; Di Li; Man Zhou; Yan Li
Journal:  J Inflamm Res       Date:  2021-12-24

Review 4.  Interleukin-22 in Renal Protection and Its Pathological Role in Kidney Diseases.

Authors:  Qianqian Ma; Jingyun Luan; Yu Bai; Caili Xu; Fangyu Liu; Bufeng Chen; Dianwen Ju; Hong Xu
Journal:  Front Immunol       Date:  2022-03-31       Impact factor: 7.561

5.  Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics.

Authors:  Peter Garred; Andrea J Tenner; Tom E Mollnes
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

6.  MiR-92d-3p suppresses the progression of diabetic nephropathy renal fibrosis by inhibiting the C3/HMGB1/TGF-β1 pathway.

Authors:  Yuhua Zhang
Journal:  Biosci Rep       Date:  2021-09-30       Impact factor: 3.840

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.